tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Berney T et al. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. 2004 Transplant. Proc. pmid:15194390
Gonzalez Molina M et al. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine. 2007 Transplant. Proc. pmid:17889126
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Kobayashi M et al. HLA-DR matching effect in orthotopic liver transplantation under FK 506. 1993 Transplant. Proc. pmid:7679812
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Masutani K et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. 2014 Transplant. Proc. pmid:24655972
Gavela E et al. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715842
Cherala G et al. Tacrolimus pharmacokinetics in Hispanic children after kidney transplantation. 2011 Transplant. Proc. pmid:22172831
Spinelli GA et al. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. 2011 Transplant. Proc. pmid:22172836
Latorre A et al. Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. 2002 Transplant. Proc. pmid:11959186
Stringa P et al. Pretreatment Combination Reduces Remote Organ Damage Secondary to Intestinal Reperfusion Injury in Mice: Follow-up Study. Transplant. Proc. pmid:26915870
Soda M et al. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Transplant. Proc. pmid:28736028
Mac Guad R et al. Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:26915847
Fitzsimmons WE et al. Demographic considerations in tacrolimus pharmacokinetics. 1998 Transplant. Proc. pmid:9636552
Burke GW et al. Tacrolimus-related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. 1998 Transplant. Proc. pmid:9532223
Shimizu T et al. Risk factors of acute tacrolimus nephrotoxicity in renal allografts. 2000 Transplant. Proc. pmid:11119998
Bonet H et al. Survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. 1993 Transplant. Proc. pmid:7680145
Chueh SC et al. Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report. 2000 Transplant. Proc. pmid:11120003
Lauro A et al. Results of intestinal and multivisceral transplantation in adult patients: Italian experience. 2006 Jul-Aug Transplant. Proc. pmid:16908252
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Takeda M et al. Methotrexate in rescue therapy for xenotransplanted lungs in primates. 1996 Transplant. Proc. pmid:8623402
Burkhalter F et al. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. 2012 Transplant. Proc. pmid:23195006
Andereggen E et al. Immunohistological study of islet xenograft rejection in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623420
Charco R et al. Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation. 2005 Transplant. Proc. pmid:16386588
Mueller AR et al. Influence of immunosuppression on patient outcome after liver transplantation. 1998 Transplant. Proc. pmid:9636608
Kawauchi M et al. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolims, filtration plasmapheresis, and nafamstat mesilate. 1994 Transplant. Proc. pmid:7518105
Oppenheimer F Steroid withdrawal in renal transplant recipients. 2000 Transplant. Proc. pmid:10686314
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Hairhara Y et al. Effect of fluconazole on blood levels of tacrolimus. 1999 Transplant. Proc. pmid:10578284
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Jain A et al. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. 2005 Transplant. Proc. pmid:15848671
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Chen J et al. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. 2008 Transplant. Proc. pmid:18589119
Marcén R et al. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. 2006 Transplant. Proc. pmid:17097957
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Borrows R et al. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results. 2005 Transplant. Proc. pmid:15919468
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Gozdowska J et al. Safety and tolerance of sodium mycophenolate in patients after renal transplantation--an observational study. 2009 Transplant. Proc. pmid:19857665
Varo E et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. 2002 Transplant. Proc. pmid:12176481
Odoul F et al. Massive ingestion of tacrolimus in a young liver transplant patient. 1998 Transplant. Proc. pmid:9865375
Cronin DC et al. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. 1997 Feb-Mar Transplant. Proc. pmid:9123010
Rossi G et al. Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907932
Morphopathological findings of renal allografts under FK 506 therapy. Japanese FK 506 Study Group. 1994 Transplant. Proc. pmid:7520614
Choi JY and Kwon OJ Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants? 2013 Transplant. Proc. pmid:24156999
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Mange KC and Bloom RD Rates of acute rejection by recipient race and type of calcineurin inhibitor with mycophenolate mofetil. 2002 Transplant. Proc. pmid:12493393
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Domenech N et al. Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. 2003 Transplant. Proc. pmid:12962873
Boots JM et al. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? 2002 Transplant. Proc. pmid:12493409
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Peraira JR et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. 2003 Transplant. Proc. pmid:12962875
Villanueva ME et al. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation. 2008 Transplant. Proc. pmid:18790198
Wayman MR et al. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. 2002 Transplant. Proc. pmid:12176526
Cho WH et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. 2008 Transplant. Proc. pmid:18790201
Okamoto M et al. Tacrolimus-based immunosuppression in renal transplantation: 78 experiences in a single Japanese center. 2002 Transplant. Proc. pmid:12176527
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Limsrichamrern S et al. Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27320581
Guo Z et al. Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123314
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Schweizer RT and Meisterling LD Tolerability of mycophenolate mofetil in organ transplant recipients. 2001 Transplant. Proc. pmid:11377540
Pham SM et al. Sirolimus and tacrolimus in clinical cardiac transplantation. 2002 Transplant. Proc. pmid:12176597
Zhou J et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. 2008 Transplant. Proc. pmid:19100435
Ciancio G et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267169
Vincenti F Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. 2001 Feb-Mar Transplant. Proc. pmid:11267172
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Ghio L et al. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. 2004 Transplant. Proc. pmid:15251325
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Grabczewska Z et al. Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index. 2013 Transplant. Proc. pmid:23726621
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Murase N et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. 1987 Transplant. Proc. pmid:2445081
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Shokouh-Amiri MH et al. The importance of early prevention of renal dysfunction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267345
Pankewycz O et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. 2011 Transplant. Proc. pmid:21440749
García González M et al. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. 1999 Transplant. Proc. pmid:10500620
Fu Q et al. Risk Factors for Acute Rejection After Deceased Donor Kidney Transplantation in China. 2018 Transplant. Proc. pmid:30316380
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Pinho-Apezzato ML et al. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. 2010 Transplant. Proc. pmid:20620519
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Rodriguez Cubillo B et al. Risk Factors of Recurrence of Diabetic Nephropathy in Renal Transplants. 2016 Transplant. Proc. pmid:27932117
Kinukawa T et al. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. 1998 Transplant. Proc. pmid:9636498
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Nielsen FT et al. Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. 1994 Transplant. Proc. pmid:7527946
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947